chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a public health, healthcare professional refers to unspecified patients of unknown age and gender. On an unknown date the unspecified patients might had vaccinated with improperly stored M-M-R II (lot #, dose, frequency and route unspecified), which were exposed to 53F for 12 hours and M-M-R II (lot#, dose, frequency and route unspecified), which were exposed to 54F for five hours. No adverse effects reported. Follow up information has been received from an office manager concerning a patient. On 20-SEP-2013 the patient was vaccinated with improperly stored M-M-R II (H018181, exp. 05-OCT-2014), which were exposed to 54F for 5 hours (date excursion ended 06-SEP-2013). This is one of several reports received from the same source (linked MARRS#: 1311USA007619, 1311USA011609, 1311USA011610, 1311USA011611, 1311USA011612, 1311USA011613, 1311USA011614, 1311USA011616, 1311USA011615, 1311USA011618, 1311USA011619). Additional information has been requested.
Pt recv vax on 12/18/98; on same day pt exp chills, legs weak, tender & erythema at vax site
This spontaneous report as received from a licensed practical nurse refers to a multiple unspecified patients of unknown age and gender. On unknown dates, the patients were vaccinated with improperly stored doses of MMR II (lot # K003822 exp date 14-MAR-2016 and lot # K024038 exp date 26-NOV-2016) (dose and route not reported). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
started her period/has not had a period in over a year/had been bleeding very bad on period/ hasn't had her period in over a year but she has been bleeding a lot down there; Fever/  Running a High Fever; This is a spontaneous report from a contactable consumer (patient's son). A 50-year-old female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, lot number and expiry date unknown), via an unspecified route of administration on 04May2021 as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient's son called to report that his mother received the second dose on an unspecified date and on 05May2021 she experienced a fever and has started her period. The reporter stated that the patient has not had a period in over a year. The patient had been bleeding very bad on period and she kept getting all that and she has been running a high fever. She hasn't had her period in over a year but she has been bleeding a lot down there. The reporter was wondering if he should take her to the hospital or if this was just normal. The patient did not receive treatment for the events. The outcome of the events was not recovered.   Information on the lot/batch number has been requested.
issues with breathing; injection site is swollen red and hot; fever; injection site is swollen red and hot; injection site is swollen red and hot; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (issues with breathing), VACCINATION SITE WARMTH (injection site is swollen red and hot), PYREXIA (fever), VACCINATION SITE SWELLING (injection site is swollen red and hot) and VACCINATION SITE ERYTHEMA (injection site is swollen red and hot) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Dec-2021, the patient experienced DYSPNOEA (issues with breathing), VACCINATION SITE WARMTH (injection site is swollen red and hot), PYREXIA (fever), VACCINATION SITE SWELLING (injection site is swollen red and hot) and VACCINATION SITE ERYTHEMA (injection site is swollen red and hot). At the time of the report, DYSPNOEA (issues with breathing), VACCINATION SITE WARMTH (injection site is swollen red and hot), PYREXIA (fever), VACCINATION SITE SWELLING (injection site is swollen red and hot) and VACCINATION SITE ERYTHEMA (injection site is swollen red and hot) outcome was unknown.       No concomitant medication were reported.   No Treatment drug were not reported.
itching and redness developed about 1 week after injection. Looks like a red ring around where the shot was given. Will take benedryl to see if it helps with the itching but do not think this is serious enough to be treated at my doctors office.
At the moment of the infection I felt nothing. When I stood up and unfolded mi arm I felt a shooting pain along mi arm all the way to my fingers( don't remember exactly which fingers) and I started to feel my arm get hot from the site of injection towards my fingers. It lasted for about 1 to 2 minutes. And I had a residual shooting pain for about 5 minutes, coming and going. Then at 9 pm I had my fingers completely swollen, I couldn't take my rings off. I still have my hand swollen. My arm has the normal pain that the injections is supposed to give, I can't raise my arm quite well without having pain on it.
Within ten minutes of receiving DTaP #4, Prevnar #1 and Influenza #1 facial hives, erythema, several on back and two on abdomen. Site immediately at prevnar injection site slighty swollen and red. Rubbing face. Given orapred in office, Benadryl at home.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. On an unknown date, the patient was vaccinated with a dose of PROQUAD (Merck) (dose, frequency, route of administration were not provided; lot # K025760, expiration date 08-JUN-2016) that had been improperly stored. No adverse effects reported. This is one of several reports from the same reporter. Additional information has been requested.
Neck pain night after vaccines given. Then a circular area about 1/4 in diameter (L) upper thigh developed with multiple papules & small blisters that has persisted since.
This spontaneous report as received from a other health professional refers to a 6 year old patient. On 11-JUL-2014 the patient was vaccinated with MMR II (HSA, lot # J015503, EXP 05-DEC-2015 dose and route not reported) which was stored improperly. There was no adverse effect reported. This is one of several reports received from the same source. Additional information is not expected.
Information has been received from a certified medical assistant concerning a 17 year old female with no pertinent medical history and no known drug reactions/allergies who on 06-AUG-2008 was vaccinated with a dose of GARDASIL and a dose of VARIVAX (Merck). there was no concomitant medication. On 09-AUG-2008 the patient experienced a swollen feeling in her neck and difficulty breathing. Subsequently the patient recovered from swollen feeling in her neck and difficulty breathing. At the time of the nurse report. The patient's medical chart was not available. The patient sought medical attention at the emergency room. Additional information has been requested.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) in a 23-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jun-2021 at 12:09 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 22-Jun-2021 at 12:09 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.     Concomitant products were not provided.  On 22-jun-2021, Excursion time was 08AM, temperature was 35, total doses given for the day was 36, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 27-may-2021, vial was moved to clinic on 22-jun-2021. 4 vials were sent to clinic. Vaccine BUD date was 26-jun-2021 for 8am.  On 22-jun-2021, vials were stored in cooler 1, at following time and temperature respectively, 8 AM: 35, 9 AM: 39, 10 AM: 47, 11 AM: 36, 12 AM: 42, 1PM: 43, 2 PM: 43, 3 PM: 43 and 4 PM: 43.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Swelling; Redness; mild Flu-like Symptoms; Wrong route of administration; This case was reported by a pharmacist via call center representative and described the occurrence of swelling in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date).   On 15th June 2019, the patient received the 2nd dose of Shingrix (subcutaneous). On an unknown date, less than 3 months after receiving Shingrix, the patient experienced swelling, erythema, influenza-like symptoms and intramuscular formulation administered by other route. On an unknown date, the outcome of the swelling, erythema, influenza-like symptoms and intramuscular formulation administered by other route were unknown.   It was unknown if the reporter considered the swelling, erythema and influenza-like symptoms to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported, but the patient was in their 60's. The pharmacist reported that another pharmacist gave the second dose of Shingrix subcutaneously, which led to intramuscular formulation administered by other route. The patient reported redness, swelling and mild flu-like symptoms after receiving the vaccine. The reporter consented to follow up.   The pharmacist did not have any further of the data for the report.
On about April 28 give or take a day, I noticed a small red soar like an irritated ugly mean sore not open but threatening like. I got the vaccine in the right arm but these are all in the left lower middle arm. Then two more. This went on for a week and then I started to put rubbing alcohol and in the last 3 days I put Antiseptic Iodine solution 10% Now today I have about four more, total about 7 or 8. They are redish and appear to have flesh raw like around the middle. They are about 1/16 to 1/8 inch in size. It is scary and they dont go away and nothing seems to help get rid of them.  I dont know if I should get the 2nd vaccine as is to be done this friday.
I initially developed a painful injection site, which was to be expected. A few days post injection I then developed a rash directly over the injection site which was roughly 1 inch x 2 inches in diameter. More than a month later, I noticed the return of mild soreness at my injection site. While examining the site, I felt and visualized an obvious depression in my arm, also about 1 in x 2 inches in diameter, which appears to be muscle atrophy.
Following the vaccination I was well except for a headache that kept coming and going. On Jan 28 I woke with an angry red patch at the injection site (3?).  It was hot, slightly raised and very kitchy. I made an appointment for a virtual consultation with my doctor for 1pm. In the meantime I took a Zyrtec. Taking the Zyrtec helped immediately. By the time i spoke to the doctor you could hardly see the redness (I did take a picture of before Zyrtec). The doctor said it was obviously an allergic reaction to the COVID shot. To keep taking Zyrtec for 4 days. Go to emergency room if it got worse, etc.  I am now fine.
Patient states redness, soreness, and swollen arm from Prevnar still one week post vaccination. Low grade fever went away. Patient states this happened with previous pneumonia vaccine as well.
Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; Administered vaccine that was stored at temperature between -80 degree F to -84 degree F; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 076C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Nov-2021 at 3:10 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 16-Nov-2021 at 3:10 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) and PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree F to -84 degree F) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were provided. Reporter stated that on an unknown date the facility had a temperature excursion for the Moderna COVID-19 vaccine and the excursion duration was 1 month. And also, the vaccine was stored in an ultra cold freezer at -82 degrees Fahrenheit. On 19-Nov-2021 the Moderna COVID-19 vials went from the super cold freezer to the refrigerator. 70 vials were in the ultra cold freezer, 8 vials were in the refrigerator. The vaccine was never refrozen. Number of vials impacted were 78 and none of the vials were punctured and there were no previous temperature excursions.   This case was linked to MOD-2021-402935 (Patient Link).
Fever; Chills; Nausea; Chest tightness for almost 2 hours thatwas coming and going and felt likepressure on chest,; Squeezing chest; Welts; bumpy rash that looks like bug bites on  lower  back,upper back, both legs, chest and on  face; bumpy rash that looks like bug bites that are itchy, on  lower back, upper back, both legs, chest and on face; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 18Apr2021 at 11:30 (at the age of 55-year-old) as a single dose for COVID-19 immunization. Patient did not have any medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any medication within two weeks of vaccination. The patient did not have allergies to medications, food, or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 28Mar2021 at 12:30 (at the age of 55-year-old) as a single dose for COVID-19 immunization. Post second vaccination, the patient had fever and chills and nausea the next morning, second night had chest tightness for almost 2 hours that was coming and going and felt like pressure on chest, was not hard to breathe but was like squeezing chest, 2nd day had welts and bumpy rash that looks like bug bites that are itchy, on lower back, upper back, both legs, chest and on face. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken for the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, nausea, chest tightness for almost 2 hours, felt like pressure on chest, was not hard to breathe but was like squeezing chest, welts and bumpy rash that looks like bug bites that are itchy, on lower back, upper back, both legs, chest and on face was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Local erythema 7.5 cm vertically 4.5 cm horizontally. No fluctuance, no color Recommended ibuprofen and ice
Patient had vaccine appointment at 5:00 I spoke with patient prior to receiving vaccine regarding allergies and was told she was allergic to rocephin, sulpha, erythromycin and penicillin. Patient was given vaccine Moderna first dose 0.5ml in left arm by technician. She waited the 15 minutes and then at 530 patient and mom came up stating that she was having shortness of breath and some chest tightness and throat itching. I had patient sit and took her blood pressure and gave Benadryl. Her first reading was 165/108 no help to the itchy ness so we gave another benadryl then retook blood pressure at 541 it was 132/93. Patient was still having feeling of knot in throat and was given epipen around 545 and called 911, we retook after epipen and bp was 128/95 and heart rate was 135 at 550. took it one more time and it had gone back up to 147/96 and then the ambulance was here and took the patient away.
Her rectum was bleeding, it was bright red blood; Her arm was also sore the same day she received the vaccine; A spontaneous report was received from a consumer concerning a 91-years-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced bloody diarrhea and pain in extremity.  The patient's medical history was not provided. Concomitant medications included warfarin.    On 16 Mar 2021, prior to the onset of the events, the patient received their second of two planned doses of mRNA-1273 (Batch Number: 024M20A) intramuscularly for prophylaxis of COVID-19 infection.  On 16 Mar 2021, the patient experienced arm was sore the same day she received the vaccine, but it went away the next day. On 19 Mar 2021, the patient experienced rectal bleeding, which was bright red blood and one bout of diarrhea. No treatment information was provided.   Action taken with the drug in response to the events was not applicable.  The outcome of the events were reported as resolved.; Reporter's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.
Information has been received from a registered nurse regarding an unspecified co-worker of an unknown age and gender who had a diagnosis of breast cancer and was receiving chemotherapy. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (dose and lot number were not provided). On an unknown date, the patient contracted the shingles shortly after preparing and administering the ZOSTAVAX. VZVID Packet not offered as this took place years ago.  At the time of the report, the patient's outcome was unknown. Additional information is not expected.
She was itching and had red "hives".  Was sent to ER from Employee Health Services.
pt recv vax & devel redness @ the inj site which persisted for @ least 4-5 days
Chills; full body ache; headache; temperature of 102 Fahrenheit; This is a spontaneous report from a contactable reporter (patient). This 22-year-old non-pregnant female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number ER8736) via an unspecified route of administration in the left arm on 21Apr2021 at 18:45 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history included generalized anxiety disorder, attention deficit hyperactivity disorder, major depressive disorder, and asthma, all from unknown dates and unknown if ongoing. The patient had no known allergies. Prior to vaccination the patient had not been diagnosed with COVID. Concomitant medications included methylphenidate hydrochloride (CONCERTA), sertraline hydrochloride (ZOLOFT), diphenhydramine hydrochloride (BENADRYL), vortioxetine hydrobromide (TRINTELLIX) and bupropion hydrobromide (APLENZIN), all taken from unspecified dates for unspecified indications. The patient previously received the first dose of BNT162B2 (lot number ER8737) on 31Mar2021 at 06:45 (at the age of 22-years-old) for COVID-19 immunisation. On 22Apr2021 at 12:00 the patient experienced chills, full body ache, headache, and temperature of 102 Fahrenheit. It was unknown if treatment was received for the events. The events were reported as non-serious and did not require hospitalization. The clinical outcomes of chills, full body ache, headache and temperature of 102 Fahrenheit were recovering. It was also reported that since vaccination the patient had not been tested for COVID.  No follow-up attempts are needed. No further information is expected.
fever and was hospitalized with gastrointestinal bleeding.; fever and was hospitalized with gastrointestinal bleeding.; abdominal pain; vomiting with blood; This is a spontaneous report from a non-contactable consumer. A 77-year-old male patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot: unknown), via an unspecified route of administration on 26Feb2021 at SINGLE DOSE for COVID-19 immunisation. The patient had no other vaccine in four weeks. The patient had no COVID prior vaccination. The patient's medical history was not reported. Concomitant medication included dabigatran etexilate mesilate (PRADAXA) taken for a year. Historical vaccine includes first dose of (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot: unknown) on 05Feb2021 for COVID-19 immunisation. On 09Mar2021, the patient experienced fever and was hospitalized with gastrointestinal bleeding, abdominal pain, and vomiting with blood. The events caused hospitalization on an unspecified date. It was reported that patient had COVID test post vaccination on 10Mar2021 with unknown results. Therapeutic measures were taken as a result of all events. The outcome of all events was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
School RN contacted outreach clinic RN to let me know this patient's mother stated her daughter's TIV injection site had some oozing and was swollen up to 2 days after injection.  Patient was seen by her PCP, topical antibiotic cream given per mom, and was fine by next day.
We were doing an off-site vaccine clinic with multiple vaccinations available.  Pt stated he got Pfizer on round 1, and had lost his card.  I administered the vaccine while my documenter was looking up his information to fill out a new card.  We then discovered his first dose was actually Moderna 025B21A.   No harm has come to this patient.
Patient was administered a pfizer purple cap dose past the beyond use date.  Patient was observed for the full 15 minute waiting period and didn't seem to have any type of adverse event occur.  We wanted to document just in case something were to occur later.